Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bristol Myers Squibb Co. (BMY), AstraZeneca plc (ADR) (AZN): Expanding P/E Saved This Pharma Investment

Page 1 of 2

So much for Bristol Myers Squibb Co. (NYSE:BMY)‘s long-term post-Plavix guidance.

Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year. This year’s adjusted earnings were supposed to be at least $1.95 per share, higher than the company had in 2009.

Today, the pharma company said it expects adjusted earnings for this year to come in between $1.70 to $1.78 per share, down from the $1.78 to $1.88 per share estimate that Bristol Myers Squibb Co. (NYSE:BMY) gave at the beginning of the year, and well below the $1.85 per share Bristol-Myers posted in 2009.

Blame it on the new kids
There was no doubt that Plavix sales were going to plummet; second-quarter sales were down 94% year over year. Bristol Myers Squibb Co. (NYSE:BMY) needed the new drugs to step up and fill the gap, but that didn’t happen.

Bristol Myers Squibb Co. (NYSE:BMY)Diabetes drug Bydureon, which Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN) picked up in the acquisition of Amylin, produced sales of just $66 million in the second quarter. The drug, which only has to be injected weekly, was supposed to have much higher demand than the twice-daily formulation Byetta, which brought in $104 million in the second quarter. Eli Lilly & Co. (NYSE:LLY) selling back the drugs to Amylin might have been the pharma’s best move of 2011 — perhaps this decade — the company hasn’t had that many wins recently.

Investors also have high hopes for Eliquis, which Bristol Myers Squibb Co. (NYSE:BMY) sells with Pfizer Inc. (NYSE:PFE), but the drug managed just $12 million in the second quarter, down from $17 million in its first quarter of the launch. The lower sales are likely due to stocking in the first quarter, but even so, it’s clear Bristol-Myers and Pfizer are having a challenging time penetrating the heart-drug market. Eliquis has to compete with Bayer and Johnson & Johnson (NYSE:JNJ)‘s Xarelto and Boehringer Ingelheim’s Pradaxa, which had a year or more head start. Sales of Xarelto in the second quarter came in at $189 million in the second quarter, nearly four times as much as Johnson & Johnson and Bayer sold in the year-ago quarter, so there’s clearly a market for the drugs. Pfizer and Bristol-Myers just need to put a little more muscle into the marketing.

Changing expectations
Despite having gone nowhere with earnings — backwards actually — shares have increased more than 70% since the original long-term guidance was issued, trumping the S&P 500.

BMY Chart

BMY data by YCharts

Page 1 of 2
Loading Comments...